Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission

Wyeth

Status and phase

Completed

Phase 4

Conditions

Depression

Treatments

Drug: Effexor® (Venlafaxine)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00546494

0600B-101547

Details and patient eligibility

About

This is a study to determine the utility of Effexor® (venlafaxine) in achieving response, including time to response, maintaining remission, and time to remission as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D) and to determine the utility of Effexor® (venlafxine) on the various cluster of symptom scales in the 17-item HAM-D.

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients meeting criteria for a diagnosis of major depression, single or recurrent episode as described by the DSM-IV manual (appendix 1).
A HAM-D 17 total score of at least 16 at baseline (DSM-IV manual, appendix 2).
Patients above 18 years of age who meet the eligibility requirements.

Exclusion criteria

Patients taking MAOI's within 2 weeks prior to the survey.
Patients known to be suffering from bipolar disorder or schizophrenia.
Patients who are treatment-resistant, i.e., in the past 3 years have failed (a) three previous adequate trials of greater than or equal to 2 classes of antidepressant medication, or (b) electroconvulsive therapy.
Drug or alcohol dependence or abuse in the past 6 months per DSM IV criteria.